​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals (VRTX) stock forecast, based on 56 Wall Street analysts, predicts a 12-month average price target of $555.93, with a high of $617.00 and a low of $350.00. This represents a 4.96% increase from the last price of $529.65.

$350 $410 $470 $530 $590 $650 High: $617 Avg: $555.93 Low: $350 Last Closed Price: $529.65

VRTX Stock Rating

Vertex Pharmaceuticals stock's rating consensus is Buy, based on 56 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 47 Buy (83.93%), 8 Hold (14.29%), 1 Sell (1.79%), and 0 Strong Sell (0.00%).

Buy
Total 56 1 8 47 Strong Sell Sell Hold Buy Strong Buy

VRTX Price Target Upside V Benchmarks

TypeNameUpside
StockVertex Pharmaceuticals4.96%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts91246
Avg Price Target$559.33$541.33$532.85
Last Closing Price$529.65$529.65$529.65
Upside/Downside5.60%2.21%0.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 2641941129
Jul, 2662141133
Jun, 2662151-33
May, 2652151-32
Apr, 2652241133
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 11, 2026Jeffrey WalchBernstein$608.00$530.2914.65%14.79%
Aug 10, 2026Andy ChenWolfe Research$562.00$522.787.50%6.11%
Aug 05, 2026Truist Financial$565.00$488.5615.65%6.67%
Aug 05, 2026Barclays$617.00$478.7128.89%16.49%
Aug 04, 2026Cantor Fitzgerald$595.00$470.7226.40%12.34%
Aug 04, 2026Canaccord Genuity$442.00$470.72-6.10%-16.55%
Aug 04, 2026Stifel Nicolaus$500.00$470.726.22%-5.60%
Jul 13, 2026UBS$585.00$481.7021.44%10.45%
Jul 13, 2026Truist Financial$560.00$479.0216.91%5.73%
Jul 07, 2026RBC Capital$570.00$529.597.63%7.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 12, 2026RBC CapitalOutperformOutperformhold
Aug 11, 2026BernsteinOutperformOutperformhold
Aug 10, 2026Wolfe ResearchOutperformOutperformhold
Aug 10, 2026BMO CapitalOutperformOutperformhold
Aug 05, 2026BarclaysOverweightOverweighthold
Aug 04, 2026Cowen & Co.BuyBuyhold
Aug 04, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 13, 2026UBSBuyBuyhold
Jul 07, 2026BMO CapitalOutperformOutperformhold
Jul 07, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.09$12.97$14.05$-2.08$15.46---
Avg Forecast$12.96$14.60$15.03$0.48$18.47$20.49$22.97$25.82
High Forecast$14.54$16.11$15.40$1.12$19.96$25.45$28.82$29.56
Low Forecast$12.26$13.86$14.65$0.06$16.67$17.06$19.12$24.25
Surprise %-29.86%-11.16%-6.52%-533.33%-16.30%---

Revenue Forecast

$7B $9B $11B $13B $15B $17B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.57B$8.93B$9.87B$11.02B$12.00B---
Avg Forecast$7.50B$8.93B$9.86B$10.89B$11.77B$12.86B$13.94B$15.25B
High Forecast$8.21B$9.64B$9.91B$10.97B$13.68B$12.87B$14.04B$16.94B
Low Forecast$7.19B$8.58B$9.79B$10.85B$11.22B$12.85B$13.85B$14.53B
Surprise %0.97%-0.03%0.06%1.17%1.97%---

Net Income Forecast

$-1B $800M $3B $4B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.34B$3.32B$3.62B$-535.60M$3.95B---
Avg Forecast$2.08B$2.40B$3.62B$153.32M$4.77B$4.87B$5.30B$6.73B
High Forecast$2.50B$2.88B$4.34B$291.61M$5.20B$6.63B$7.51B$7.70B
Low Forecast$1.66B$1.92B$2.90B$15.03M$4.34B$4.44B$4.98B$6.32B
Surprise %12.58%38.24%--449.33%-17.14%---

VRTX Forecast FAQ

Is Vertex Pharmaceuticals stock a buy?

Vertex Pharmaceuticals stock has a consensus rating of Buy, based on 56 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 47 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Vertex Pharmaceuticals is a favorable investment for most analysts.

What is Vertex Pharmaceuticals's price target?

Vertex Pharmaceuticals's price target, set by 56 Wall Street analysts, averages $555.93 over the next 12 months. The price target range spans from $350 at the low end to $617 at the high end, suggesting a potential 4.96% change from the previous closing price of $529.65.

How does Vertex Pharmaceuticals stock forecast compare to its benchmarks?

Vertex Pharmaceuticals's stock forecast shows a 4.96% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vertex Pharmaceuticals over the past three months?

  • August 2026: 13.79% Strong Buy, 65.52% Buy, 13.79% Hold, 3.45% Sell, 3.45% Strong Sell.
  • July 2026: 18.18% Strong Buy, 63.64% Buy, 12.12% Hold, 3.03% Sell, 3.03% Strong Sell.
  • June 2026: 18.18% Strong Buy, 63.64% Buy, 15.15% Hold, 3.03% Sell, 0% Strong Sell.

What is Vertex Pharmaceuticals’s EPS forecast?

Vertex Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $20.49, marking a 32.54% increase from the reported $15.46 in 2025. Estimates for the following years are $22.97 in 2027, and $25.82 in 2028.

What is Vertex Pharmaceuticals’s revenue forecast?

Vertex Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $12.86B, reflecting a 7.17% increase from the reported $12B in 2025. The forecast for 2027 is $13.94B, and $15.25B for 2028.

What is Vertex Pharmaceuticals’s net income forecast?

Vertex Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.87B, representing an 23.31% increase from the reported $3.95B in 2025. Projections indicate $5.3B in 2027, and $6.73B in 2028.